Evidence map›Paper›PMID 28639131›Full record

ArticleDigestive diseases and sciences2017

miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature.

Silvia Fittipaldi, Francesco Vasuri, Sonia Bonora, Alessio Degiovanni, Giacomo Santandrea, Alessandro Cucchetti, Laura Gramantieri, Luigi Bolondi, Antonia D'Errico

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Silvia Fittipaldi"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy.
Francesco Vasuri"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy. vasurifrancesco@libero.it.
Sonia Bonora"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy.
Alessio Degiovanni"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy.
Giacomo Santandrea"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy.
Alessandro CucchettiDepartment of Medical and Surgical Sciences (DIMEC), S. Orsola-Malpighi University Hospital, Bologna, Italy.
Laura GramantieriDivision of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Luigi BolondiDivision of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, S. Orsola-Malpighi University Hospital, Bologna, Italy.
Antonia D'Errico"F. Addarii" Institute of Oncology and Transplant Pathology, Department of Specialty, Diagnostic and Experimental Medicine (DIMES), S. Orsola-Malpighi University Hospital, V.le Ercolani 4/2, 40138, Bologna, Italy.
Policlinico S.Orsola-Malpighi · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmiRNA deregulation and vascular modifications constitute promising predictors in the study of hepatocellular carcinoma (HCC). In the literature, the relative miRNA abundance in HCC is usually determined using as control non-matched tumoral tissue, healthy liver, or cirrhotic liver. However, a common standard RNA control for the normalization toward the tissue gene expression was not settled yet.

aimTo assess the differences existing in the quantitative miRNA gene expression in HCC on tissue according to two different liver controls.

methodsA wide array of miRNAs was analyzed on 22 HCCs arisen in cirrhotic and non-cirrhotic livers by means of microfluidic cards. Control samples included total RNA extracted from healthy and cirrhotic livers. Immunohistochemistry for CD34 and Nestin was performed to assess the pattern of intratumoral vascular modifications.

resultsSix miRNAs were deregulated in HCCs using either controls: miR-532, miR-34a, miR-93, miR-149#, miR-7f-2#, and miR-30a-5p. Notably, the miRNA expression changed significantly between HCCs arisen in cirrhotic and non-cirrhotic livers, according to the control used for normalization. Different miRNA profiles were found also in HCCs with different vascular patterns, according to the control used for normalization.

conclusionsOur data confirm that the choice of the methodology, and particularly the control used for normalization, represents the main concern in miRNA evaluation, particularly in a heterogeneous model such as liver pathology. Still we observed the deregulation of some common miRNAs as promising in HCC cancerogenesis and progression. A standardized control will be a crucial achievement to compare miRNA expression among different laboratories.

Indexed as

Gene Expression Regulation, NeoplasticAgedAged, 80 and overAnimalsBiomarkers, TumorCarcinoma, HepatocellularDisease ProgressionFemaleHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedNeovascularization, PathologicRetrospective StudiesBiomarkers, TumorMicroRNAsCirrhosisHepatocellular carcinomaMicrofluidic cardmiRNANeoangiogenesis

Identifiers

PMID28639131
OpenAlexW2680748954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.